Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS10040202HBVENSG00000157404.17protein_codingKITYesNo3815P10721
TVIS10040086HBVENSG00000157404.17protein_codingKITYesNo3815P10721
TVIS30010849HIVENSG00000157404.17protein_codingKITYesNo3815P10721
TVIS20037373HPVENSG00000157404.17protein_codingKITYesNo3815P10721
TVIS20039601HPVENSG00000157404.17protein_codingKITYesNo3815P10721
TVIS44012431HTLV-1ENSG00000157404.17protein_codingKITYesNo3815P10721
TCGA Plot Options
Drug Information
GeneKIT
DrugBank IDDB01254
Drug NameDasatinib
Target IDBE0000453
UniProt IDP10721
Regulation Typeantagonist
PubMed IDs16397263; 16434489; 17351742
CitationsSchittenhelm MM, Shiraga S, Schroeder A, Corbin AS, Griffith D, Lee FY, Bokemeyer C, Deininger MW, Druker BJ, Heinrich MC: Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res. 2006 Jan 1;66(1):473-81.@@Shah NP, Lee FY, Luo R, Jiang Y, Donker M, Akin C: Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood. 2006 Jul 1;108(1):286-91. Epub 2006 Jan 24.@@Dizdar O, Dede DS, Bulut N, Altundag K: Dasatinib may also inhibit c-Kit in triple negative breast cancer cell lines. Breast Cancer Res Treat. 2008 Jan;107(2):303. Epub 2007 Mar 10.
GroupsApproved; Investigational
Direct ClassificationAromatic anilides
SMILESCC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
PathwaysDasatinib Inhibition of BCR-ABL
PharmGKBPA162372878
ChEMBLCHEMBL1421